PROTHENA CORPORATION PUBLIC LIMITED COMPANY Common Stock, Value, Issued
PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) had Common Stock, Value, Issued of $517.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:CommonStockValue · last filed 2026-08-06
- 2026-06-30: Common Stock, Value, Issued $517.00K.
- 2026-03-31: Common Stock, Value, Issued $530.00K.
- 2025-12-31: Common Stock, Value, Issued $538.00K.
- 2025-09-30: Common Stock, Value, Issued $538.00K.
| Period end | Common Stock, Value, Issued |
|---|---|
| 2026-06-30 | $517.00K 10-Q · filed 2026-08-06 |
| 2026-03-31 | $530.00K 10-Q · filed 2026-05-07 |
| 2025-12-31 | $538.00K 10-Q · filed 2026-08-06 |
| 2025-09-30 | $538.00K 10-Q · filed 2025-11-06 |
| 2025-06-30 | $538.00K 10-Q · filed 2025-08-04 |
| 2025-03-31 | $538.00K 10-Q · filed 2025-05-08 |
| 2024-12-31 | $538.00K 10-K · filed 2026-02-27 |
| 2024-09-30 | $538.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $538.00K 10-Q · filed 2024-08-08 |
| 2024-03-31 | $537.00K 10-Q · filed 2024-05-08 |
| 2023-12-31 | $537.00K 10-K · filed 2025-02-27 |
| 2023-09-30 | $536.00K 10-Q · filed 2023-11-02 |
| 2023-06-30 | $535.00K 10-Q · filed 2023-08-03 |
| 2023-03-31 | $527.00K 10-Q · filed 2023-05-04 |
| 2022-12-31 | $521.00K 10-K · filed 2024-02-22 |
| 2022-09-30 | $479.00K 10-Q · filed 2022-11-03 |
| 2022-06-30 | $468.00K 10-Q · filed 2022-08-08 |
| 2022-03-31 | $467.00K 10-Q · filed 2022-05-05 |
| 2021-12-31 | $466.00K 10-K · filed 2023-02-28 |
| 2021-09-30 | $465.00K 10-Q · filed 2021-11-04 |
| 2021-06-30 | $449.00K 10-Q · filed 2021-08-05 |
| 2021-03-31 | $442.00K 10-Q · filed 2021-05-11 |
| 2020-12-31 | $399.00K 10-K · filed 2022-02-25 |
| 2020-09-30 | $399.00K 10-Q · filed 2020-11-04 |
| 2020-06-30 | $399.00K 10-Q · filed 2020-08-06 |
| 2020-03-31 | $399.00K 10-Q · filed 2020-05-06 |
| 2019-12-31 | $399.00K 10-K · filed 2021-02-26 |
| 2019-09-30 | $399.00K 10-Q · filed 2019-11-05 |
| 2019-06-30 | $399.00K 10-Q · filed 2019-08-06 |
| 2019-03-31 | $399.00K 10-Q · filed 2019-05-07 |
| 2018-12-31 | $399.00K 10-K · filed 2020-03-03 |
| 2018-09-30 | $398.00K 10-Q · filed 2018-11-06 |
| 2018-06-30 | $398.00K 10-Q · filed 2018-08-07 |
| 2018-03-31 | $398.00K 10-Q · filed 2018-05-09 |
| 2017-12-31 | $385.00K 10-K · filed 2019-03-15 |
| 2017-09-30 | $384.00K 10-Q · filed 2017-11-07 |
| 2017-06-30 | $382.00K 10-Q · filed 2017-08-09 |
| 2017-03-31 | $380.00K 10-Q · filed 2017-05-09 |
| 2016-12-31 | $348.00K 10-K · filed 2018-02-26 |
| 2016-09-30 | $344.00K 10-Q · filed 2016-11-02 |
| 2016-06-30 | $343.00K 10-Q · filed 2016-08-02 |
| 2016-03-31 | $343.00K 10-Q · filed 2016-05-04 |
| 2015-12-31 | $317.00K 10-K · filed 2017-02-27 |
| 2015-09-30 | $315.00K 10-Q · filed 2015-11-02 |
| 2015-06-30 | $314.00K 10-Q · filed 2015-08-05 |
| 2015-03-31 | $275.00K 10-Q · filed 2015-05-06 |
| 2014-12-31 | $274.00K 10-K · filed 2016-02-25 |
| 2014-09-30 | $274.00K 10-Q · filed 2014-11-04 |
| 2014-06-30 | $267.00K 10-Q · filed 2014-08-05 |
| 2014-03-31 | $219.00K 10-Q · filed 2014-05-05 |
| 2013-12-31 | $219.00K 10-K · filed 2015-03-13 |
| 2013-09-30 | $177.00K 10-Q · filed 2013-11-12 |
| 2013-06-30 | $177.00K 10-Q · filed 2013-08-13 |
| 2013-03-31 | $177.00K 10-Q · filed 2013-05-15 |
| 2012-12-31 | $177.00K 10-K · filed 2014-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |